Cite
HARVARD Citation
Ang, M. et al. (2021). Phase II study of nimotuzumab (TheraCim‐hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head & neck. 43 (5), pp. 1641-1651. [Online].